Profile
Jeffrey McDonald worked as the Director of Information Technology at Lipomics Technologies, Inc. from 2001 to 2009.
Prior to that, he obtained an undergraduate degree from the University of California, Davis.
Former positions of Jeffrey McDonald
| Companies | Position | End |
|---|---|---|
Lipomics Technologies, Inc.
 Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | Chief Tech/Sci/R&D Officer | 11/09/2009 |
Training of Jeffrey McDonald
| University of California, Davis | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Lipomics Technologies, Inc.
Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | Health Technology |
- Stock Market
- Insiders
- Jeffrey McDonald
